Sugi Predict

Sugi Predict / Targets / SLC5A1

SLC5A1

Sodium/glucose cotransporter 1 · P13866 · SLC5A1 on Sugi Atlas →

50,984 patent compounds predicted against SLC5A1, 28,558 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL500113 SCHEMBL500113 0.78 19/20
SCHEMBL500041 SCHEMBL500041 0.81 18/20
SCHEMBL499736 SCHEMBL499736 0.78 18/20
SCHEMBL173842 SCHEMBL173842 0.70 18/20
SCHEMBL48129 SCHEMBL48129 0.64 18/20
SCHEMBL48226 SCHEMBL48226 0.57 18/20
SCHEMBL17758 SCHEMBL17758 0.84 17/20
SCHEMBL18128 SCHEMBL18128 0.84 17/20
SCHEMBL18772 SCHEMBL18772 0.84 17/20
SCHEMBL17305 SCHEMBL17305 0.82 17/20
SCHEMBL18014 SCHEMBL18014 0.80 17/20
SCHEMBL18219 SCHEMBL18219 0.80 17/20
SCHEMBL18233 SCHEMBL18233 0.75 17/20
SCHEMBL18369 SCHEMBL18369 0.75 17/20
SCHEMBL17459 SCHEMBL17459 0.74 17/20
SCHEMBL17530 SCHEMBL17530 0.74 17/20
SCHEMBL18098 SCHEMBL18098 0.74 17/20
SCHEMBL18394 SCHEMBL18394 0.74 17/20
SCHEMBL18917 SCHEMBL18917 0.74 17/20
SCHEMBL24323 SCHEMBL24323 0.74 17/20

Clinical trials — most relevant to SLC5A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients PHASE4COMPLETED
Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy PHASE4COMPLETED
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes PHASE4COMPLETED
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES PHASE4UNKNOWN
Effect of Anti-diabetic Drugs on Glycemic Variability PHASE4COMPLETED
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. PHASE4COMPLETED
Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy PHASE4COMPLETED
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration PHASE4COMPLETED
Dapagliflozin Effect on Erythropoiesis and Physical Fitness PHASE4WITHDRAWN
SGLT2i, Pioglitazone, and Ketone Production in T1D PHASE3NOT_YET_RECRUITING
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients PHASE3UNKNOWN
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes PHASE2COMPLETED
Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin PHASE2NOT_YET_RECRUITING
Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure PHASE2COMPLETED
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure PHASE2COMPLETED
Empagliflozin in ESKD - A Feasibility Study PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PK and PD of YG1699 in CKD Patients With Diabetes PHASE1NOT_YET_RECRUITING
Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients nanCOMPLETED
Real Life Evaluation of SGLT2 Use in Type 1 Diabetes nanWITHDRAWN
DIA_CENTRAL:T2D Treatment Pattern in Central Europe nanCOMPLETED
Head-to-head Comparison of Empagliflozin and Dapagliflozin nanCOMPLETED
Impact of SGLT2 Inhibitors on Chronic Peritoneal Dialysis Patients. nanRECRUITING
Impact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial Infarction nanCOMPLETED
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity nanRECRUITING
Dapagliflozin in the Treatment of Heart Failure nanUNKNOWN
Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy nanUNKNOWN
Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors nanCOMPLETED
Impact of SGLT2 on Glucosuria in HNF1A-MODY nanCOMPLETED
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) nanUNKNOWN
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC5A1 binder may also engage these)

ProteinNameSimilarity
P53790 — 1.000 P53790 →
P11170 — 0.999 P11170 →
D3ZIS0 — 0.996 D3ZIS0 →
SLC5A11 Sodium/myo-inositol cotransporter 2 0.995 landscape →
Q8C3K6 — 0.995 Q8C3K6 →
P26429 — 0.995 P26429 →
Q9ET37 — 0.995 Q9ET37 →
Q9NY91 — 0.994 Q9NY91 →
P53791 — 0.994 P53791 →
Q3ZC26 — 0.994 Q3ZC26 →
P31636 — 0.993 P31636 →
Q91ZP4 — 0.992 Q91ZP4 →
Q2M3M2 — 0.990 Q2M3M2 →
Q5SWY8 — 0.990 Q5SWY8 →
P53793 — 0.989 P53793 →
A8WHP3 — 0.989 A8WHP3 →
Q8UWF0 — 0.986 Q8UWF0 →
A0PJK1 — 0.984 A0PJK1 →
P31637 — 0.984 P31637 →
Q8BGY9 — 0.983 Q8BGY9 →
Q9JKZ2 — 0.983 Q9JKZ2 →
A8I1B9 — 0.982 A8I1B9 →
Q9Z1F2 — 0.982 Q9Z1F2 →
P53794 — 0.982 P53794 →
Q9JMD7 — 0.981 Q9JMD7 →
Q28610 — 0.981 Q28610 →
Q95XG8 — 0.981 Q95XG8 →
Q8VDT1 — 0.980 Q8VDT1 →
Q8K0E3 — 0.980 Q8K0E3 →
SLC5A7 High affinity choline transporter 1 0.979 landscape →